2019/07/31
(寄稿)
Identifying Product Value When Entering the US Biopharma Market
Summary
- The US marketplace alone accounts for nearly 50% of worldwide pharmaceutical revenues
- Companies seeking to enter the US biopharma market need to identify partners that can assist in developing an understanding of the product value associated with their asset
- To ascertain a range of value requires a detailed process that models a multitude of dynamic market factors
- This valuation process is ongoing and not a one-time event
- The magnitude of analysis increases commensurate with each of Phase of clinical development, as do the costs of this activity
- Companies considering entry into the US marketplace should therefore invest in efforts to identify the estimated value of their asset, however, the investment should be right-sized given the stage of development
- The US marketplace alone accounts for nearly 50% of worldwide pharmaceutical revenues
- Companies seeking to enter the US biopharma market need to identify partners that can assist in developing an understanding of the product value associated with their asset
- To ascertain a range of value requires a detailed process that models a multitude of dynamic market factors
- This valuation process is ongoing and not a one-time event
- The magnitude of analysis increases commensurate with each of Phase of clinical development, as do the costs of this activity
- Companies considering entry into the US marketplace should therefore invest in efforts to identify the estimated value of their asset, however, the investment should be right-sized given the stage of development
(Continued..)
連載記事
